Published on: June 23, 2025 | Author: Peter Cook, PhD | Seattle Children's Research Institute
Meta Description (SEO): Discover how DARIC CAR T cells are revolutionizing autoimmune disease therapy by selectively targeting plasma cells with drug-inducible precision. Breakthrough research from Seattle Children’s Research Institute.
What Are DARIC CAR T Cells?
DARIC (Drug-Activated Receptor Immune Complex) CAR T cells represent an innovative approach in immunotherapy, developed to selectively eliminate plasma cells that produce harmful antibodies in autoimmune diseases. These cells are engineered to target BCMA (B-cell maturation antigen) but only become active in the presence of a small molecule drug—rapamycin.
Without the drug, the CAR T cells remain inactive, offering a unique safety and timing mechanism.
Key Findings from Preclinical Research
In Vitro (Lab Results)
- DARIC CAR T cells effectively killed differentiated plasma cells.
- Undifferentiated B-cells remained unaffected.
- The system was activated only with the administration of rapamycin.
In Vivo (Animal Models)
- In humanized mice models, DARIC cells eliminated plasma cells.
- Human IgG and IgM levels dropped significantly when rapamycin was present.
Clinical Relevance
This therapy could provide targeted treatment for:
- Autoimmune diseases like lupus, vasculitis, and Sjögren’s syndrome.
- Organ transplant rejection, where donor-specific antibodies pose a threat.
As CD19-targeted CAR T therapies cannot eliminate plasma cells, DARIC offers a more specific and controlled approach.
Challenges and Future Directions
Current Challenge:
- High manufacturing cost and complexity of CAR T therapy.
Future Vision:
- In vivo delivery of DARIC genes to T-cells using viral vectors.
- Disease-specific animal models (e.g., skin graft models) to validate efficacy.
Final Thoughts
DARIC CAR T cells are paving a new path in treating antibody-driven autoimmune conditions with precision and safety. As research advances, this technology could redefine immunotherapy in autoimmunity.
Source: ASGCT 2024 Presentation, Abstract #1258 by Peter Cook, PhD
